Kết quả bước đầu điều trị bổ trợ capecitabine trên bệnh nhân ung thư vòm giai đoạn III-IVA sau hoá xạ đồng thời=Preliminary results of adjuvant capecitabine treatment following concurrent chemoradiotherapy in stage III-IVA nasopharyngeal carcinoma patients

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Hùng Kiên Đỗ, Văn Tài Nguyễn

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam (Tổng hội Y học Việt Nam), 2024

Mô tả vật lý: tr.44-51

Bộ sưu tập: Metadata

ID: 478110

Thêm vào giỏ

Đánh giá tỷ lệ kiểm soát bệnh, thời gian sống thêm không tiến triển và một số tác dụng không mong muốn của phác đồ bổ trợ capecitabine sau hoá xạ đồng thời trên bệnh nhân ung thư vòm giai đoạn III-IVA tại bệnh viện K. Đối tượng và phương pháp nghiên cứu: Nghiên cứu mô tả cắt ngang tiến hành trên 36 bệnh nhân ung thư vòm giai đoạn III-IVA được điều trị hoá xạ đồng thời và hoá chất bổ trợ capecitabine tại bệnh viện K từ 01/2022 đến 8/2024. Kết quả: Bệnh nhân chủ yếu ở giai đoạn IVA (61,1%), hay gặp giai đoạn u T3-4 (80,6%). Giai đoạn N2 chiếm 52,8%. Phần lớn bệnh nhân có điều trị hoá chất cảm ứng (88,9%). Trong hoá xạ đồng thời, điều trị cisplatin tổng liều  200mg/m2 đạt 91,7%. Kết quả bước đầu bổ trợ capecitabine cho thấy tỷ lệ kiểm soát bệnh đạt 97,3%. Sống thêm không tiến triển tại thời điểm 3 năm là 85,4%. Về độc tính, đa phần độc tính độ 1-2, chỉ gặp độ 3 ở 2,8% bệnh nhân, trong đó có nôn, buồn nôn
hội chứng bàn tay-bàn chân, hạ bạch cầu và thiếu máu. Kết luận: Phác đồ bổ trợ capecitabine có kết quả bước đầu đem lại lợi ích về thời gian sống thêm và dung nạp tương đối tốt trên bệnh nhân ung thư vòm giai đoạn III-IVA đã hoá xạ đồng thời.To evaluate the disease control rate, progression-free survival (PFS), and adverse effects of the adjuvant capecitabine regimen following concurrent chemoradiotherapy in stage III-IVA nasopharyngeal cancer patients at K hospital. Patients and Methods: The descriptive cross-sectional study was conducted on stage IIIIVA nasopharyngeal cancer patients who received concurrent chemoradiotherapy and adjuvant capecitabine treatment at K hospital from January 2022 to August 2024. Results: 36 patients were included in the study. Majority of them were in stage IVA (61.1%), with tumor stages being T3-4 (80.6%). N2 stage accounted for 52.8%. Most patients received induction chemotherapy (88.9%). During concurrent chemoradiotherapy, 91.7% of patients received a total dose of cisplatin of ≥200 mg/m². Preliminary results of adjuvant capecitabine showed a disease control rate of 97.3%. The 3-year PFS was 85.4%. Regarding adverse events (AEs), most were of grade 1-2, with grade 3 AE observed in only 2.8% of patients, including nausea, vomiting, hand-foot syndrome, leukopenia, and anemia. Conclusion: The adjuvant capecitabine regimen following concurrent chemoradiotherapy shows initial benefits in survival and relatively good tolerance in stage III-IVA nasopharyngeal cancer patients.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR